


## CLAIMS

1. A compound of formula (I)



or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

$R^1$  is  $C_{1-4}$  alkyl or  $C_{3-6}$  cycloalkyl, wherein said alkyl is optionally substituted by pyridyl or pyridyl N-oxide;

$R^2$  is  $C_{1-4}$  alkyl,  $C_{3-6}$  cycloalkyl, or trifluoromethyl;

$R^3$  is  $-(CH_2)_m OR^4$ ,  $-(CH_2)_m OC(O)NH_2$ ,  $-(CH_2)_m NH_2$ , or  $-(CH_2)_m NHC(O)NH_2$ ;

$R^4$  is H or  $C_{1-4}$  alkyl;

$m$  is 1, 2, 3 or 4.

2. A compound according to claim 1, wherein at least one of the following conditions is fulfilled:

- $R^1$  is methyl, ethyl, i-propyl, cyclopropyl, or pyridylmethyl;
- $R^2$  is methyl, ethyl, n-propyl, i-propyl, cyclopropyl, or trifluoromethyl;
- $R^3$  is  $-(CH_2)_m OR^4$  or  $-(CH_2)_m OC(O)NH_2$ ;
- $R^4$  is H.

3. A compound according to claim 1, which is selected from the group consisting of:

5-[3,5-Diethyl-2-(2-hydroxyethyl)-3H-imidazol-4-ylsulfanyl]-isophthalonitrile;

5-[5-Cyclopropyl-3-ethyl-2-(2-hydroxyethyl)-3H-imidazol-4-ylsulfanyl]-

isophthalonitrile;

5-[3-Ethyl-2-hydroxymethyl-5-isopropyl-3H-imidazol-4-ylsulfanyl]-isophthalonitrile;

5-[3-Ethyl-2-(2-hydroxyethyl)-5-trifluoromethyl-3H-imidazol-4-ylsulfanyl]-isophthalonitrile;

Carbamic acid 4-Cyclopropyl-5-(3,5-dicyano-phenylsulfanyl)-1-ethyl-1H-imidazol-

2-ylmethyl ester;

Carbamic acid 5-(3,5-Dicyano-phenylsulfanyl)-1-ethyl-4-isopropyl-1H-imidazol-2-ylmethyl ester;

Carbamic acid 5-(3,5-dicyano-phenylsulfanyl)-1,4-diethyl-1H-imidazol-2-ylmethyl ester;

Carbamic acid 5-(3,5-dicyano-phenylsulfanyl)-1-ethyl-4-(trifluoromethyl)-1H-imidazol-2-ylmethyl ester;

- 5 5-[2-Hydroxymethyl-5-isopropyl-3-(pyridin-4-ylmethyl)-3H-imidazol-4-ylsulfanyl]-isophthalonitrile;  
5-[2-(2-Hydroxyethyl)-5-isopropyl-3-methyl-3H-imidazol-4-ylsulfanyl]-isophthalonitrile;  
5-[3-Ethyl-2-(2-hydroxyethyl)-5-isopropyl-3H-imidazol-4-ylsulfanyl]-  
10 isophthalonitrile;  
and pharmaceutically acceptable salts, solvates or derivatives thereof.

4. A pharmaceutical composition comprising a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, according to any  
15 of claims 1 to 3, together with one or more pharmaceutically acceptable excipients, diluents or carriers.

5. A pharmaceutical composition according to claim 4 including one or more additional therapeutic agents.

20

6. A compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 3, or a pharmaceutical composition according to claim 4 or 5, for use as a medicament.

- 25 7. A compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 3, or a pharmaceutical composition according to claim 4 or 5, for use as a reverse transcriptase inhibitor or modulator.

- 30 8. A compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 3, or a pharmaceutical composition according to claim 4 or 5, for use in the treatment of a HIV, a retroviral infection genetically related to HIV, or AIDS.

- 35 9. The use of a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 3, or a pharmaceutical composition according to claim 4 or 5, in the manufacture of a medicament having reverse transcriptase inhibitory or modulating activity.

10. The use of a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 3, or a pharmaceutical composition according to claim 4 or 5, in the manufacture of a medicament for the treatment of a HIV, a retroviral infection genetically related to HIV, or AIDS.
11. A method of treatment of a mammal, including a human being, with a reverse transcriptase inhibitor or modulator, which comprises treating said mammal with an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 3, or a pharmaceutical composition according to claim 4 or 5.
12. A method of treatment of a mammal, including a human being, with a HIV, a retroviral infection genetically related to HIV, or AIDS, which comprises treating said mammal with an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 3, or a pharmaceutical composition according to claim 4 or 5.
13. A process for preparing compounds of formula (I) comprising:  
a) alkylation of a compound of formula (II) with  $R^1X$ , or  
b) reaction of a compound of formula (XIII) with a compound of formula (IV) or (V).
14. A process according to claim 13 wherein the preparation of a compound of formula (II) comprises reacting a compound of formula (III) with a compound of formula (IV) or (V).
15. A compound of formula (II), (III), (IV) or (V).